DOCSLIB.ORG

Guide to the Management of Gabapentinoid Misuse

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Guide to the Management of Gabapentinoid Misuse THERAPY FOCUS ■ Guide to the management of gabapentinoid misuse GRAHAM PARSONS In light of the SPL government’s proposals to reclassify pregabalin and gabapentin as Class C controlled drugs due to the risk of misuse, this article examines the extent of the problem of gabapentinoid misuse and its effects, and provides practical advice to prescribers on reducing these harms. regabalin was launched in the UK Pin 2004 while gabapentin was first authorised in the UK in 1997. Both drugs were originally licensed for seizure dis­ orders but now have multiple licensed indications. In England during 2016, over current (licensed and unlicensed) indica­ 12 million prescription items were dis­ tions and the pharmacology of the two pensed for gabapentinoids as a group.1 drugs, aspects of their misuse potential The Advisory Council on the Misuse of and effects of this misuse on the indi­ Drugs (ACMD) reported that pregabalin vidual. Finally, it provides advice for prescribing in the UK increased by 350% prescribers on managing the misuse of in the five years to 2012 while gabapen­ gabapentinoids and supporting patients tin prescribing increased by 150% during who are discontinuing a gabapentinoid. the same period.2 There has been growing concern Licensed uses about the misuse potential of the gaba­ The gabapentinoids have a wide range pentinoids as a group and in particular of licensed uses. Pregabalin and gaba­ pregabalin, as reported in the 2016 pentin are both licensed for neuropathic ACMD review of this class of drugs.2 This pain and epilepsy.3,4 Pregabalin also has concern led to the government launch­ a licence for the treatment of generalised ing a consultation on the reclassification anxiety disorder (GAD).3 Pregabalin is of pregabalin and gabapentin as Class recommended by NICE as a second­line C controlled drugs under the Misuse of pharmacotherapy for GAD if a patient Drugs Act, which ended on 22 January cannot tolerate SSRIs or SNRIs.5 NICE 2018.1 recommends offering a choice of amitrip­ This article discusses both drugs but tyline, duloxetine, gabapentin or pregab­ with a particular emphasis on pregaba­ alin as initial treatment for neuropathic lin, which presents with a greater misuse pain (except trigeminal neuralgia).6 Off­ potential than gabapentin. It explores the label uses for gabapentinoids include prescriber.co.uk Prescriber April 2018 ❚ 25 ■ THERAPY FOCUS l Gabapentinoid misuse the treatment of migraine, alcohol use • Presenting intoxicated, impaired or dishevelled (especially if this is a change to disorders, mania and bipolar disorder.7 the normal presentation) NICE recommends early and regu­ • Loss of interest in alternative pleasures or activities (the medication becomes lar assessments of patients prescribed the focus) pharmacotherapies for neuropathic • Early requests for prescriptions pain, including the gabapentinoids. The • ‘Lost’ prescriptions assessment should include dosage titra­ • Increasing use of current prescription due to unsanctioned dose increases tion, tolerability and adverse effects.6 • Concurrent misuse of related illicit drugs While markers for potential misuse (see • Acquisition of medication from other sources, eg out­of­hours services Table 1) may emerge later in treatment, • Subjective and objective withdrawals when the patient does not have the medication prescribers should always be alert to • No interest in the diagnosis (the medication becomes the focus) these even at the start of a treatment • Failure to keep appointments for further diagnostic tests or refusal to see episode so that misuse can be avoided. another practitioner for consultation • Worsening mental health presentation Pharmacology • Aggressive complaining Both gabapentin and pregabalin are • Reporting unintended psychotropic effects from prescription medication structurally similar to the inhibitory neu­ • Prescription forgery rotransmitter gamma­aminobutyric acid (GABA) and rapidly cross the blood­brain Table 1. Markers for potential misuse of gabapentinoids barrier. The gabapentinoids bind to the alpha­2­delta subunit of the voltage­de­ bility is reported as 60% for a 300mg needed to provide a similar psychoactive pendent calcium channels in the CNS capsule.4 Gabapentin is also eliminated effect. Mixed misuse with antipsychotic resulting in a decrease in the excitatory unchanged through renal excretion with drugs can also be a problem – as demon­ neurotransmitters glutamate, noradrena­ an elimination half­life of between five to strated in a case report describing the line, substance P and calcitonin gene­re­ seven hours.4 misuse of gabapentin and quetiapine.9 lated peptide. Both drugs produce Pregabalin and gabapentin have also pharmacological effects that are sim­ Why are gabapentinoids been used to enhance the effects of ilar in nature to those produced by the misused? alcohol and other prescribed and non­pre­ inhibitory neurotransmitter GABA, ie they Gabapentinoids have been reported to scribed drugs including methadone.7,8,10 exhibit GABA­mimetic properties. produce alcohol/gamma hydroxybutyrate Animal models also support the hypoth­ Pregabalin is rapidly absorbed on (GHB)/benzodiazepine­type effects esis that the effects of morphine and an empty stomach with peak plasma mixed with euphoria. Rates of euphoria pregabalin are potentiated when taken concentrations occurring within one have been reported at between 1 and together. hour. It has a high bioavailability (≥90%) 12% but this has been for therapeutic The onset of action of the gabapenti­ and a mean elimination half­life of 6.3 doses.8 Other reported actions include noids ranges from between 10 minutes, hours and undergoes almost no metab­ dissociative effects, improved sociability, ie quick acting, and two hours depend­ olism with the parent drug being largely relaxation and sense of calm, and psy­ ing on the route of administration and excreted unchanged in the urine. The chedelic effects. both dependent and recreational use linear pharmacokinetics of pregabalin Schifano et al. reported that signifi­ has been reported. Rapid development (compared with the non­linear phar­ cant psychotropic effects are associated and extinction of tolerance to the effects macokinetics of gabapentin) allows with higher doses and “idiosyncratic (ie of gabapentinoids has also been docu­ straightforward dosing regimens and a IV, rectal, intranasal) drug intake modali­ mented.11 predictable response. Pregabalin also ties” but the most common route of mis­ The effects associated with pregab­ has a higher binding efficiency than gaba­ use remains oral.8 alin at increasing doses, as reported by pentin and higher potency (2.5 times Polydrug misuse remains a signifi­ users, is summarised in Box 1. greater than gabapentin). The higher cant concern with the cohort of service potency, quicker absorption and greater users that may misuse gabapentinoids Evidence for and prevalence of availability of pregabalin vs gabapentin and has been implicated in the recent gabapentinoid misuse makes pregabalin more attractive as a rise in drug­related deaths for the gaba­ There is now a rich source of anecdotal drug of misuse pentinoids. A recent review in the jour­ reports that support significant misuse of The absorption of gabapentin follow­ nal Addiction suggests that pregabalin gabapentinoids both in the UK and inter­ ing oral administration is less rapid than is used to enhance the effects of heroin nationally, such as the user reports on pregabalin. Peak plasma concentrations but for some people it may also be used the Erowid website.12 Following the intro­ are observed within two to three hours to help support the reduction in use of duction of pregabalin to the UK in 2004, with oral bioavailability decreasing with heroin.7 This synergistic effect can also the Medicines and Healthcare products increasing dose. Absolute bioavaila­ be used to reduce the amount of heroin Regulatory Agency (MHRA) received its 26 ❚ Prescriber April 2018 prescriber.co.uk Gabapentinoid misuse l THERAPY FOCUS ■ which increased to 15–22% within “opi­ According to pregabalin (mis)users, different doses are associated with a vast oid abuse samples”.18 range of effects: Drug-related deaths and 600mg: stumbling, disorientation, increased physical and psychological gabapentinoid misuse awareness, difficulty driving, slurred and broken speech, hearing and visual The CNS depressant effects of the gaba­ alterations/hallucinations, double and blurred vision, uninhibited behaviours, pentinoids and opioids (drowsiness, talkativeness, increased body energy, increased sexual performance respiratory depression and respiratory failure) are a significant risk and have 900mg: strong feelings of drunkenness, difficulty walking, alteration of colour been implicated in drug­related deaths. perception, little euphoria Deaths where gabapentinoids were men­ tioned on death certificates in England 1200mg: drowsiness, euphoria, entactogenic (empathetic) feelings, ie similar to and Wales have increased from less than Ecstasy one a year before 2009 to 137 deaths in 2015.7 In 79% of these deaths, opioids >1500mg (to 5g): uncontrollable drowsiness, frequent hallucinations, great were also mentioned. This increase in euphoria, frequent dissociative events (described as dextromethorphan/DXM­like drug­related deaths was also shown to dissociative effects), behavioural inhibition, anxiety, and necessity to move correlate highly with prescribing data, ie increased prescribing of gabapentinoids Box 1. Online user accounts of pregabalin effects,
Load more

Recommended publications
  • Métrologie De La Douleur Animale Sur Modèles Expérimentaux : Développement Et Validation De Biomarqueurs Neuroprotéomiques
    Université de Montréal Métrologie de la douleur animale sur modèles expérimentaux : développement et validation de biomarqueurs neuroprotéomiques. par Colombe Otis Département de biomédecine vétérinaire Faculté de médecine vétérinaire Thèse présentée à la Faculté de médecine vétérinaire en vue de l’obtention du grade de philosophiæ doctor (Ph. D.) en sciences vétérinaires option pharmacologie Août, 2017 © Colombe Otis, 2017 Résumé La douleur est un phénomène complexe et dynamique comprenant un processus primaire et sensoriel, la nociception, auquel se rajoutent des réactions de défense et d'alarme psychophysiologiques. Ceci conduit au développement d'une véritable mémoire de la douleur, individuelle et modulée (plasticité neuronale) par des expériences précédentes de douleur, incluant entre autres, des phénomènes de sensibilisation nociceptive. Pour bien comprendre les mécanismes de sensibilisation centrale, les modèles animaux mimant les pathologies humaines sont d’une importance primordi ale. Or, pour ce faire, nous avons proposé une série d'approches expérimentales translationnelles par le développement de modèles expérimentaux de douleur bovine, canine et murine afin de caractériser les atteintes du protéome spinal en fonction du niveau de douleur perçu par l'animal et d’identifier le (les) marqueur (s) potentiellement modulé (s) par la sensibilisation nociceptive. À l’aide de la neuroprotéomique, nous avons identifié sur un modèle bovin de douleur viscérale, la protéine transthyrétine (TTR) comme étant sous-exprimée dans le protéome spinal en présence de douleur et ce, vérifié également dans le modèle canin de douleur chronique liée à l’arthrose chirurgicale. Ces résultats suggèrent la possibilité d’entrevoir la TTR comme un biomarqueur potentiel de la douleur chronique. Notre découverte de la relation entre les niveaux spinaux de TTR par neuroprotéomique et l’ hypersensibilité à la douleur dans les modèles bovin et canin soutiennent l’implication de composantes inflammatoires nociceptives et immunitaires.
    [Show full text]
  • Chapter 25 Mechanisms of Action of Antiepileptic Drugs
    Chapter 25 Mechanisms of action of antiepileptic drugs GRAEME J. SILLS Department of Molecular and Clinical Pharmacology, University of Liverpool _________________________________________________________________________ Introduction The serendipitous discovery of the anticonvulsant properties of phenobarbital in 1912 marked the foundation of the modern pharmacotherapy of epilepsy. The subsequent 70 years saw the introduction of phenytoin, ethosuximide, carbamazepine, sodium valproate and a range of benzodiazepines. Collectively, these compounds have come to be regarded as the ‘established’ antiepileptic drugs (AEDs). A concerted period of development of drugs for epilepsy throughout the 1980s and 1990s has resulted (to date) in 16 new agents being licensed as add-on treatment for difficult-to-control adult and/or paediatric epilepsy, with some becoming available as monotherapy for newly diagnosed patients. Together, these have become known as the ‘modern’ AEDs. Throughout this period of unprecedented drug development, there have also been considerable advances in our understanding of how antiepileptic agents exert their effects at the cellular level. AEDs are neither preventive nor curative and are employed solely as a means of controlling symptoms (i.e. suppression of seizures). Recurrent seizure activity is the manifestation of an intermittent and excessive hyperexcitability of the nervous system and, while the pharmacological minutiae of currently marketed AEDs remain to be completely unravelled, these agents essentially redress the balance between neuronal excitation and inhibition. Three major classes of mechanism are recognised: modulation of voltage-gated ion channels; enhancement of gamma-aminobutyric acid (GABA)-mediated inhibitory neurotransmission; and attenuation of glutamate-mediated excitatory neurotransmission. The principal pharmacological targets of currently available AEDs are highlighted in Table 1 and discussed further below.
    [Show full text]
  • “GABA” 'Bout? Pregabalin and Gabapentin Abuse
    3/19/18 What’s All the “GABA” ‘Bout? Pregabalin and Gabapentin Abuse Courtney Kominek, PharmD, BCPS, CPE Disclosures .Courtney Kominek, PharmD, BCPS, CPE –Axial Healthcare – Consultant .The views and opinions expressed in this presentation are those of the authors and do not necessarily reflect the official policy or position of any agency of the United States government, including the Department of Veterans Affairs. 1 3/19/18 Learning Objectives .Review the proposed mechanisms of action (MOA) for gabapentin and pregabalin. .Explain the proposed rationale as to why gabapentin and pregabalin have become drugs of abuse. .Identify signs and symptoms of withdrawal that an addicted or tolerant patient may experience upon abrupt discontinuation of gabapentin or pregabalin. .Discuss updates on changes in pain management given the increase in gabapentin and pregabalin abuse. Current Situation Opioid overdose public health crisis Rising use of nonopioid medications including gabapentin Opioids and concomitant gabapentin increase risk for overdose Reports of gabapentinoid abuse Changes in PDMP and scheduling at state level http://www.register-herald.com/news/manchin-asks-fda-dea-to-consider-rescheduling-gabapentin/article_442fa04b-7ed9-5bf8-8d19-b5440e9c278b.html 2 3/19/18 Gabapentin and Pregabalin: Pharmacology and Pharmacokinetics Fact or Alternate Fact? .Gabapentin and pregabalin work on GABA. 3 3/19/18 Mechanism of Action Structurally related to GABA and has GABA-mimetic properties Do not • Alter uptake or breakdown • Convert into GABA • Bind to GABAa or GABAB Binds to the α2-δ subunit of the voltage-gated calcium channel Reduces the Ca2+ -dependent release of pro-nociceptive neurotransmitters Decreases release of glutamate, NE, and substance P Dworkin RH et al.
    [Show full text]
  • Gabapentin Abuse Gabapentin (Neurontin®) Is Indicated for the Treatment of Epilepsy and Neuro- Pathic Pain, Including Post-Herpetic Neuralgia
    November 2018 Poison Center Hotline: 1-800-222-1222 The Maryland Poison Center’s Monthly Update: News, Advances, Information Gabapentin Abuse Gabapentin (Neurontin®) is indicated for the treatment of epilepsy and neuro- pathic pain, including post-herpetic neuralgia. Gabapentin is often prescribed off -label for a variety of conditions including insomnia, anxiety, bipolar disorder, migraines, drug and alcohol addiction, and others. Off-label use exceeds use for FDA approved indications. Termed a gabapentinoid, it is an analog of γ- aminobutyric acid (GABA) that increases GABA but does not bind to GABA re- ceptors. It has a selective inhibitory effect on voltage-gated calcium channels containing the α2δ1 subunit. Its exact mechanism for epilepsy and pain is un- clear. Gabapentin is not a controlled substance as it was believed that gabapentin had no abuse potential when approved by the FDA in 1993. Overall, if used at thera- Did you know? peutic doses by patients without a substance abuse/misuse history, the risk of misuse is probably lower than that of other drugs such as benzodiazepines. There are reports of abuse of However, reports are increasing of gabapentin misuse and abuse. Motivations pregabalin (Lyrica ®), another for misuse include recreational use, mood and/or anxiety control, potentiating gabapentinoid used for the effects of drug abuse treatment, pain management, reducing cravings for neuropathic pain, post-herpetic other drugs, managing withdrawal from other drugs, substituting for other pain and fibromyalgia. drugs, and gabapentin addiction (Addiction 2016;11:1160-74). The risk of misuse Approved by the FDA in 2004, increases in people with a history of recreational drug abuse who take gabapen- pregabalin is Schedule V.
    [Show full text]
  • Membrane Stabilizer Medications in the Treatment of Chronic Neuropathic Pain: a Comprehensive Review
    Current Pain and Headache Reports (2019) 23: 37 https://doi.org/10.1007/s11916-019-0774-0 OTHER PAIN (A KAYE AND N VADIVELU, SECTION EDITORS) Membrane Stabilizer Medications in the Treatment of Chronic Neuropathic Pain: a Comprehensive Review Omar Viswanath1,2,3 & Ivan Urits4 & Mark R. Jones4 & Jacqueline M. Peck5 & Justin Kochanski6 & Morgan Hasegawa6 & Best Anyama7 & Alan D. Kaye7 Published online: 1 May 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review Neuropathic pain is often debilitating, severely limiting the daily lives of patients who are affected. Typically, neuropathic pain is difficult to manage and, as a result, leads to progression into a chronic condition that is, in many instances, refractory to medical management. Recent Findings Gabapentinoids, belonging to the calcium channel blocking class of drugs, have shown good efficacy in the management of chronic pain and are thus commonly utilized as first-line therapy. Various sodium channel blocking drugs, belonging to the categories of anticonvulsants and local anesthetics, have demonstrated varying degrees of efficacy in the in the treatment of neurogenic pain. Summary Though there is limited medical literature as to efficacy of any one drug, individualized multimodal therapy can provide significant analgesia to patients with chronic neuropathic pain. Keywords Neuropathic pain . Chronic pain . Ion Channel blockers . Anticonvulsants . Membrane stabilizers Introduction Neuropathic pain, which is a result of nervous system injury or lives of patients who are affected. Frequently, it is difficult to dysfunction, is often debilitating, severely limiting the daily manage and as a result leads to the progression of a chronic condition that is, in many instances, refractory to medical This article is part of the Topical Collection on Other Pain management.
    [Show full text]
  • Pregabalin for the Treatment of Drug and Alcohol Withdrawal Symptoms: a Comprehensive Review
    CNS Drugs (2016) 30:1191–1200 DOI 10.1007/s40263-016-0390-z REVIEW ARTICLE Pregabalin for the Treatment of Drug and Alcohol Withdrawal Symptoms: A Comprehensive Review 1 2,3 4 5 Rainer Freynhagen • Miroslav Backonja • Stephan Schug • Gavin Lyndon • 6 6 6 Bruce Parsons • Stephen Watt • Regina Behar Published online: 16 November 2016 Ó The Author(s) 2016. This article is published with open access at Springerlink.com Abstract Treatments for physical dependence and asso- treatment of physical dependence and accompanying ciated withdrawal symptoms following the abrupt discon- withdrawal symptoms associated with opioids, benzodi- tinuation of prescription drugs (such as opioids and azepines, nicotine, cannabinoids, and alcohol, although benzodiazepines), nicotine, alcohol, and cannabinoids are data from randomized controlled studies are sparse. How- available, but there is still a need for new and more ever, the current evidence is promising and provides a effective therapies. This review examines evidence sup- platform for future studies, including appropriate random- porting the potential use of pregabalin, an a2d voltage- ized, placebo- and/or comparator-controlled studies, to gated calcium channel subunit ligand, for the treatment of further explore the efficacy and safety of pregabalin for the physical dependence and associated withdrawal symptoms. treatment of withdrawal symptoms. Given the potential for A literature search of the MEDLINE and Cochrane Library pregabalin misuse or abuse, particularly in individuals with databases up to and including 11 December 2015 was a previous history of substance abuse, clinicians should conducted. The search term used was ‘(dependence OR exercise caution when using pregabalin in this patient withdrawal) AND pregabalin’.
    [Show full text]
  • Gabapentinoids: Pharmacokinetics, Pharmacodynamics and Considerations for Clinical Practice
    912496BJP British Journal of PainChincholkar Special Issue Article British Journal of Pain 1 –11 Gabapentinoids: pharmacokinetics, © The British Pain Society 2020 Article reuse guidelines: sagepub.com/journals-permissions pharmacodynamics and considerations DOI:https://doi.org/10.1177/2049463720912496 10.1177/2049463720912496 for clinical practice journals.sagepub.com/home/bjp Mahindra Chincholkar Abstract The gabapentinoids are often recommended as first-line treatments for the management of neuropathic pain. The differing pharmacodynamic and pharmacokinetic profiles can have implications for clinical practice. This article has summarised these key differences. In addition to their use in managing neuropathic pain, gabapentinoids are increasingly being used for off-label conditions despite the lack of evidence. Prescription rates for off-label conditions have overtaken that for on-label use. Similarly, the use of gabapentinoids in the perioperative period is now embedded in clinical practice despite conflicting evidence. This article summarises the risks associated with this increasing use. There is increasing evidence of the potential to cause harm in vulnerable populations such as the elderly and increasing prevalence of abuse. The risk of respiratory depression in combination with opioids is of particular concern in the context of the current opioid crisis. This article describes the practical considerations involved that might help guide appropriate prescribing practices. Keywords Gabapentin, pregabalin, pain management, adverse effects, pharmacology Introduction movement, sleep disorders, headaches, alcohol with- drawal syndrome, chronic back pain, fibromyalgia, vis- The gabapentinoid drugs gabapentin and pregabalin ceral pain and acute postoperative pain.4,5 The rate of are antiepileptic drugs that are considered as first-line new prescriptions is increasing and tripled in England 1 treatments for the management of neuropathic pain.
    [Show full text]
  • 1 Gabapentinoids in Total Joint Arthroplasty: the Clinical Practice
    1 Gabapentinoids in Total Joint Arthroplasty: The Clinical Practice Guidelines of the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, Hip Society, and Knee Society Charles P. Hannon MD1, Yale A. Fillingham MD2, James A. Browne MD3, Emil H Schemitsch MD FRCS(C)4, AAHKS Anesthesia & Analgesia Clinical Practice Guideline Workgroup5, Asokumar Buvanendran MD6, William G. Hamilton MD7*, Craig J. Della Valle MD1* 1Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL, USA 2Department of Orthopaedic Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA 3Department of Orthopaedic Surgery, University of Virginia, Charlottesville, VA, USA 4Department of Surgery, University of Western Ontario, London, Ontario, Canada 5Workgroup Comprised of the following individuals: Justin T. Deen MD (Department of Orthopaedics and Rehabilitation, University of Florida College of Medicine, Gainesville, FL, USA), Greg A. Erens MD (Department of Orthopaedic Surgery, Emory University, Atlanta, GA, USA), Jess H. Lonner MD (Rothman Institute at Thomas Jefferson University, Philadelphia, PA, USA), Aidin E. Pour MD (Department of orthopaedic surgery, University of Michigan, Ann Arbor, MI, USA), Robert S. Sterling MD (Department of Orthopedic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA) 6Department of Anesthesiology, Rush University Medical Center, Chicago, IL, USA 7Anderson Orthopedic Research Institute, Alexandria, VA, USA *Denotes co-senior authors 2 Introduction The American Association of Hip and Knee Surgeons (AAHKS), The American Academy of Orthopaedic Surgeons (AAOS), The Hip Society, The Knee Society and The American Society of Regional Anesthesia and Pain Medicine (ASRA) have worked together to develop evidence-based guidelines on the use of gabapentinoids in primary total joint arthroplasty (TJA).
    [Show full text]
  • Intranasal Pregabalin Administration: a Review of the Literature and the Worldwide Spontaneous Reporting System of Adverse Drug Reactions
    brain sciences Perspective Intranasal Pregabalin Administration: A Review of the Literature and the Worldwide Spontaneous Reporting System of Adverse Drug Reactions Mohamed Elsayed *, René Zeiss, Maximilian Gahr, Bernhard J. Connemann and Carlos Schönfeldt-Lecuona Department of Psychiatry and Psychotherapy III, University of Ulm, Leimgrubenweg 12-14, 89075 Ulm, Germany; [email protected] (R.Z.); [email protected] (M.G.); [email protected] (B.J.C.); [email protected] (C.S.-L.) * Correspondence: [email protected]; Tel.: +49-(0)-731-500-61411; Fax: +49-(0)-731-500-61412 Received: 2 October 2019; Accepted: 11 November 2019; Published: 13 November 2019 Abstract: Background: It is repeatedly reported that pregabalin (PRG) and gabapentin feature a potential for abuse/misuse, predominantly in patients with former or active substance use disorder. The most common route of use is oral, though reports of sublingual, intravenous, rectal, and smoking administration also exist. A narrative review was performed to provide an overview of current knowledge about nasal PRG use. Methods: A narrative review of the currently available literature of nasal PRG use was performed by searching the MEDLINE, EMBASE, and Web of Science databases. The abstracts and articles identified were reviewed and examined for relevance. Secondly, a request regarding reports of cases of nasal PRG administration was performed in the worldwide spontaneous reporting system of adverse drug reactions of the European Medicines Agency (EMA, EudraVigilance database). Results: The literature search resulted in two reported cases of nasal PRG use. In the analysis of the EMA-database, 13 reported cases of nasal PRG use (11 male (two not specified), mean age of users = 34.2 years (four not specified)) were found.
    [Show full text]
  • Gabapentin Enacarbil (Horizant) Monograph
    Gabapentin enacarbil (Horizant) Monograph ® Gabapentin Enacarbil (Horizant ) National Drug Monograph March 2012 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The purpose of VA PBM Services drug monographs is to provide a comprehensive drug review for making formulary decisions. These documents will be updated when new clinical data warrant additional formulary discussion. Documents will be placed in the Archive section when the information is deemed to be no longer current. Executive Summary: Gabapentin enacarbil (Horizant®) is a prodrug of gabapentin which binds with high affinity to the α2δ subunit of voltage-activated calcium channels in vitro studies. It is unknown how the binding of gabapentin enacarbil (GEn) to the α2δ subunit corresponds to the treatment of restless leg syndrome (RLS) symptoms. Indication: GEn is FDA approved for treatment of RLS. Pharmacokinetics: GEn is primarily excreted by the kidneys and neither gabapentin nor GEn is substrate, inhibitor, or inducer of the major CYP450 system. In addition, GEn is not an inhibitor or substrate of p-glycoprotein in vitro. Dose: The recommended dosage is 600 mg once daily taken with food at about 5 PM. Efficacy: Several studies examining GEn have shown efficacy over placebo in patients with RLS; improvement in RLS symptoms was observed within 7 days of starting treatment.6-8, 12-14 Three studies demonstrated 1200 mg/day GEn significantly reduced International Restless Legs Syndrome (IRLS) scale total score and improved Clinical Global Impression– Improvement (CGI-I) scale compared with placebo.6-8 Two studies demonstrated efficacy at lower dose of 600 mg/day GEn; however, another study did not.7,12,13 These results are comparable to those seen with dopamine agonists.8,12 Adverse Drug Events: Commonly reported adverse effects for the approved dose of 600 mg/day GEn are somnolence, sedation and dizziness.
    [Show full text]
  • Novel Treatments for Cocaine and Opioid Use Disorder
    Novel Treatments for Cocaine and Opioid Use Disorder Kyle M. Kampman M.D. Department of Psychiatry Perelman School of Medicine University of Pennsylvania [email protected] “How about cocaine?” Outline • Medications for Cocaine Use Disorder • A lot of pilot trials / a lot of failure • Topiramate +/- amphetamine for CUD • Cocaine biomarkers • Metyrapone and oxazepam for CUD • Medications for Opioid Use Disorder • Injectables / Implantables • Rapid detoxification protocols Cocaine overdose deaths are common in AAs Annals of Internal Medicine 2018 168 (6) 453-455 Targets for cocaine meds - GABAA Glu Prefrontal Cortex + & Hippocampus, PPT Glutamate Ventral Amygdala, Thalamus Pallidum D1 - D2 GABA - GABAA Glu Nucleus Glu + + Accumbens κ-opioid D1 GABA Dopamine DAT - - D2 Dynorphin - D2 Enkephalin - GABAA Ventral Output Tegmentum Treatment of cocaine dependence - topiramate Topiramate is Associated with Cocaine Abstinence Drug Alcohol Depend. 2004;75(3):233-40. Topiramate for cocaine dependence Topiramate Associated with Greater End of Trial Abstinence Drug Alcohol Depend. 2013;133(1):94-9 Topiramate for cocaine dependence Topiramate Reduced Cocaine Use JAMA Psychiatry. 2013;70(12):1338-46 Dopaminergic Medications: Dextroamphetamine Long-Acting Dextroamphetamine Reduced Cocaine Use J Clin Psychopharmacol 2001; 21:522-6 Dopaminergic Medications: Methamphetamine Long-Acting Methamphetamine Reduced Cocaine Use Drug Alcohol Depend 2009; 101:34-41 Glutamatergic / Dopaminergic Combinations: MAS + Topiramate The Combination of MAS and
    [Show full text]
  • 2020 Incentive Formularies
    2020 Incentive Formularies: This Incentive Formulary applies to members of an employer/retiree, union, or trust fund health plan For Medicare Part D: 5 Tier Incentive Formulary Please click here. For Medicare Part D: Prior Authorization Criteria Please click here. For Medicare Part D: Step Therapy Criteria Please click here. Formulary ID: 20133 Version: 22 Updated: 12/2020 Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take. When this drug list (formulary) refers to “we,” “us”, or “our,” it means Highmark Senior Health Company, Highmark Choice Company, Highmark Senior Solutions Company or HM Health Insurance Company. When it refers to “plan” or “our plan,” it means Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, or Blue Rx PDP. This document includes a list of the drugs (formulary) for our plan which is current as of 12/1/2020. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages. You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2020, and from time to time during the year. What is the Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, and Blue Rx PDP Formulary? A formulary is a list of covered drugs selected by Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, or Blue Rx PDP in consultation with a team of health care providers, which represents the prescription therapies believed to be a necessary part of a quality treatment program.
    [Show full text]